Cohort profile: The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study

International Journal of Epidemiology

Volumn 42, Issue 6, 2013, Pages 1649-1659

  Grebely, Jason ^a   Morris, Meghan D ^b   Rice, Thomas M ^b   Bruneau, Julie ^c   Cox, Andrea L ^d   Kim, Arthur Y ^e   McGovern, Barbara H ^f   Shoukry, Naglaa H ^c   Lauer, Georg ^e   Maher, Lisa ^a   Lloyd, Andrew R ^g   Hellard, Margaret ^h   Prins, Maria ^i,j   Dore, Gregory J ^a   Page, Kimberly ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d DEPARTMENT OF PATHOLOGY   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h BURNET INSTITUTE   (Australia)

ⁱ DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^j ACADEMIC MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; COHORT ANALYSIS; DATA ACQUISITION; DISEASE PREVALENCE; HEALTH SURVEY; HEPATITIS; HUMAN IMMUNODEFICIENCY VIRUS; INTERNATIONAL COOPERATION; MORTALITY; RESEARCH WORK; RNA; VIRUS;

ADULT; ARTICLE; BEHAVIORAL SCIENCE; BIOSTATISTICS; CLINICAL RESEARCH; COHORT ANALYSIS; CONTROLLED STUDY; EPIDEMIOLOGICAL DATA; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INTERNATIONAL RELATIONS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; VIROLOGY; YOUNG ADULT;

AUSTRALIA; CANADA; NETHERLANDS; UNITED STATES;

CERCOPITHECINE HERPESVIRUS 1; HEPATITIS C VIRUS;

AUSTRALIA; CANADA; COHORT STUDIES; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; NETHERLANDS; PROSPECTIVE STUDIES; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES;

EID: 84892449561     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dys167     Document Type: Article

References (32)

1. Mathers BM, Degenhardt L, Phillips B et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008;372:1733-45.
2. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol 2008;168:1099-109.
3. Nelson PK, Mathers BM, Cowie B et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011;378:571-83.
4. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 2007;18:352-58.
5. Grebely J, Tyndall MW. Management of HCV and HIV infections among people who inject drugs. Curr Opin HIV AIDS 2011;6:501-07.
6. Mathers BM, Degenhardt L, Ali H et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010;375:1014-28.
7. Grebely J, Dore GJ. Prevention of hepatitis C virus in injecting drug users: a narrow window of opportunity. J Infect Dis 2011;203:571-74.
8. Page-Shafer K, Hahn JA, Lum PJ. Preventing hepatitis C virus infection in injection drug users: risk reduction is not enough. AIDS 2007;21:1967-69.
9. Hagan H, Latka MH, Campbell JV et al. Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. Clin Infect Dis 2006;42:669-72.
10. Sacks-Davis R, Horyniak D, Grebely J, Hellard M. Behavioural interventions for preventing hepatitis C infection in people who inject drugs: a global systematic review. Int J Drug Policy 2012;23:176-84.
11. Hahn JA, Page-Shafer K, Lum PJ et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 2002;186:1558-64.
12. Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis 2011;204:74-83.
13. Corey KE, Mendez-Navarro J, Gorospe EC, Zheng H, Chung RT. Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. J Viral Hepat 2010;17:201-07.
14. Grebely J, Matthews GV, Dore GJ. Treatment of acute HCV infection. Nat Rev Gastroenterol Hepatol 2011;8:265-74.
15. Dore GJ, Hellard M, Matthews GV et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010;138:123-35.e1-22.
16. Aitken CK, Lewis J, Tracy SL et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 2008;48:1746-52.
17. Park JN, White B, Bates A, Enriquez J, Liao L, Maher L. Motivators and barriers influencing willingness to participate in candidate HCV vaccine trials: perspectives of people who inject drugs. Drug Alcohol Depend 2012;123:35-40.
18. Teutsch S, Luciani F, Scheuer N et al. Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort. BMC Public Health 2010;10:633.
19. Bruneau J, Daniel M, Kestens Y, Abrahamowicz M, Zang G. Availability of body art facilities and body art piercing do not predict hepatitis C acquisition among injection drug users in Montreal, Canada: results from a cohort study. Int J Drug Policy 2010;21:477-84.
20. van de Laar TJ, Molenkamp R, van den Berg C et al. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. J Hepatol 2009;51:667-74.
21. Cox AL, Page K, Bruneau J et al. Rare birds in North America: acute hepatitis C cohorts. Gastroenterology 2009;136:26-31.
22. Page K, Hahn JA, Evans J et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 2009;200:1216-26.
23. Cox AL, Netski DM, Mosbruger T et al. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis 2005;40:951-58.
24. McGovern BH, Wurcel A, Kim AY et al. Acute hepatitis C virus infection in incarcerated injection drug users. Clin Infect Dis 2006;42:1663-70.
25. Grebely J, Dore GJ, Schim van der Loeff M et al. Factors associated with spontaneous clearance during acute hepatitis C virus infection [Poster Abstract 1063]. J Hepatol 2010;52:S411.
26. Grebely J, Dore GJ, Schim van der Loeff M et al. Female sex and variations in IL28B are independently associated with spontaneous clearance of acute HCV infection. J Hepatol 2012; (in press).
27. Grebely J, Prins M, Hellard M et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 2012;12:408-14.
28. Mehta SH, Cox A, Hoover DR et al. Protection against persistence of hepatitis C. Lancet 2002;359:1478-83.
29. Micallef JM, Macdonald V, Jauncey M et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat 2007;14:413-18.
30. Osburn WO, Fisher BE, Dowd KA et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010;138:315-24.
31. Grebely J, Conway B, Raffa JD, Lai C, Krajden M, Tyndall MW. Hepatitis C virus reinfection in injection drug users. Hepatology 2006;44:1139-45.
32. Vickerman P, Grebely J, Dore GJ et al. The more you look the more you find-Modelling the effects of hepatitis C virus testing interval on reinfection incidence and clearance among injecting drug users. J Infect Dis 2012;205:1342-50.